Amgen Terminates $500M+ Collaboration with TScan, TScan CEO Affirms No Impact on Core Strategy

August 23, 2026

Fierce Biotech USA

Overview

Amgen has scrapped its over $500 million collaboration with TScan Therapeutics focused on immune cell therapy development. Despite this, TScan’s CEO asserted that the termination would not affect the company’s core strategy or ongoing pipeline progress. This development highlights the inherent risks and dynamic nature of large biopharmaceutical partnerships. TScan will continue to focus on its proprietary T-cell receptor (TCR) discovery platform for autoimmune diseases and cancer.

In Depth

Key Findings

Amgen has decided to terminate its collaboration agreement with TScan Therapeutics, a deal initially valued at over $500 million, which focused on the development of immune cell therapies. However, Gavin Carter, TScan’s CEO, publicly stated that this dissolution would not materially impact the company’s core research and development strategy or its existing proprietary pipeline programs.

Technical / Clinical Details

TScan possesses a unique platform designed to discover and develop novel T-cell receptors (TCRs) for the treatment of cancer and autoimmune diseases. The partnership with Amgen was specifically geared towards advancing certain immune cell therapy candidates, though the detailed reasons for the termination have not been disclosed. TScan continues to progress several internal TCR-T cell therapy programs, distinct from those targeted by Amgen, and is also advancing its diagnostic platform for identifying specific targets, none of which were reliant on the Amgen collaboration. The company’s platform aims to contribute to personalized medicine by efficiently identifying target-specific TCRs from patient T-cells.

Background & Context

Collaborations between major pharmaceutical companies and emerging biotech firms are a common strategy in the biopharmaceutical industry, serving to de-risk and accelerate technological innovation. However, such partnerships frequently face termination due to evolving clinical challenges, shifts in strategic priorities, or portfolio re-evaluations by the larger partner. Amgen’s decision may reflect a broader trend among large pharmaceutical companies to consolidate resources on their most promising internal or acquired assets, underscoring the importance for biotech firms to maintain diverse funding sources and a robust independent strategic direction.

Strategic Significance & Outlook

Despite the setback of losing a significant partner like Amgen, TScan has expressed confidence in pursuing independent growth, leveraging its strong technological foundation and multiple ongoing internal pipeline programs. The company intends to utilize its current cash reserves and resources to accelerate the development of its innovative TCR-T cell therapies in both autoimmune disease and oncology. Investors and the market will be closely watching how TScan executes its strategic objectives and delivers clinical progress in the absence of the Amgen partnership, particularly as it aims to validate its platform and bring novel therapies to patients.

Source: https://www.fiercebiotech.com/biotech

Get our weekly technology intelligence — free

Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.

Subscribe Free — Weekly Tech Intelligence

By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.